Published in J Exp Med on March 01, 1993
Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med (1994) 4.36
Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest (2003) 3.16
The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest (1994) 2.07
Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest (1999) 2.05
Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest (1994) 1.58
Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am (2007) 1.37
Blockade of CD49d (alpha4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Clin Invest (1997) 1.36
Galectin-9 in physiological and pathological conditions. Glycoconj J (2004) 1.18
Differentiation in vitro of hybrid eosinophil/basophil granulocytes: autocrine function of an eosinophil developmental intermediate. J Exp Med (1995) 1.14
Cross-talk between ICAM-1 and granulocyte-macrophage colony-stimulating factor receptor signaling modulates eosinophil survival and activation. J Immunol (2008) 1.11
Eosinophils in the 1990s: new perspectives on their role in health and disease. Postgrad Med J (1994) 1.11
Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J Clin Invest (1995) 1.03
Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res (2010) 0.97
Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis. J Clin Invest (1995) 0.97
Integrin alpha 4 beta 7 mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin. Immunology (1996) 0.95
Adhesion to fibronectin primes eosinophils via alpha 4 beta 1 (VLA-4). Immunology (1994) 0.93
'Outside-in' signalling mechanisms underlying CD11b/CD18-mediated NADPH oxidase activation in human adherent blood eosinophils. Br J Pharmacol (1999) 0.92
Eosinophils in fungus-associated allergic pulmonary disease. Front Pharmacol (2013) 0.87
The development of nasal polyp disease involves early nasal mucosal inflammation and remodelling. PLoS One (2013) 0.87
Mechanisms of eosinophil cytokine release. Mem Inst Oswaldo Cruz (2005) 0.86
Eosinophil apoptosis and clearance in asthma. J Cell Death (2013) 0.81
Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1α and MCP-1 in GM-CSF-treated human primary eosinophils. J Interferon Cytokine Res (2012) 0.77
Constitutive production of granulocyte/macrophage colony-stimulating factor by hypodense mononuclear eosinophils developed in vitro from hybrid eosinophil/basophil granulocytes. Proc Natl Acad Sci U S A (1996) 0.75
Allergy, asthma, and inflammation: which inflammatory cell type is more important? Allergy Asthma Clin Immunol (2008) 0.75
Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscriptional regulation. Cell (1987) 3.46
The eosinophil and bronchial asthma: current understanding. J Allergy Clin Immunol (1990) 3.02
An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods (1991) 2.96
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Affinity chromatographic isolation of the melanoma adhesion receptor for the IIICS region of fibronectin and its identification as the integrin alpha 4 beta 1. J Biol Chem (1990) 2.08
Human eosinophils express transforming growth factor alpha. J Exp Med (1990) 2.04
Human monocyte inflammatory mediator gene expression is selectively regulated by adherence substrates. J Immunol (1989) 2.00
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med (1991) 1.77
Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is alpha 4 beta 1 (very late antigen-4) dependent. J Immunol (1991) 1.67
Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci U S A (1991) 1.67
Mechanisms of eosinophil adherence to cultured vascular endothelial cells. Eosinophils bind to the cytokine-induced ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor. J Clin Invest (1991) 1.65
Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med (1991) 1.64
Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol (1992) 1.56
Nifedipine overdose accompanied by ethanol intoxication in a patient with congenital heart disease. J Emerg Med (1990) 1.44
Hemopoietins for eosinophils. Glycoprotein hormones that regulate the development of inflammation in eosinophilia-associated disease. Hematol Oncol Clin North Am (1989) 1.08
Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood (1992) 1.07
Observations on possible immunity to reinfection among Kenyan schoolchildren after treatment for Schistosoma mansoni. Trans R Soc Trop Med Hyg (1983) 1.05
Eosinophil activation on biologic surfaces. Production of O2- in response to physiologic soluble stimuli is differentially modulated by extracellular matrix components and endothelial cells. J Immunol (1991) 0.94
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med (1992) 11.90
Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med (1994) 4.36
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest (1991) 3.88
Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med (1999) 3.84
Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis (1990) 3.70
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2000) 3.63
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis (1988) 3.45
Non-eosinophilic corticosteroid unresponsive asthma. Lancet (1999) 3.25
Studies on eosinophil leucocyte migration. II. Factors specifically chemotactic for eosinophils and neutrophils generated from guinea-pig serum by antigen-antibody complexes. Clin Exp Immunol (1970) 3.09
Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis (1989) 3.06
Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest (1986) 2.90
Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol (1991) 2.88
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J (2007) 2.78
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax (2002) 2.63
CCR7 expression and memory T cell diversity in humans. J Immunol (2001) 2.42
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 2.38
Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ (1991) 2.32
T cells and eosinophils in the pathogenesis of asthma. Immunol Today (1992) 2.30
Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol (1997) 2.28
CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. Am Rev Respir Dis (1990) 2.18
Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. Clin Allergy (1985) 2.15
Respiratory medicine: fighting for survival. BMJ (1992) 2.15
Studies on eosinophil leucocyte migration. I. Eosinophil and neutrophil accumulation following antigen-antibody reactions in guinea-pig skin. Clin Exp Immunol (1970) 2.13
Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol (1993) 2.11
Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet (1992) 2.06
Leucoattractants enhance complement receptors on human phagocytic cells. Clin Exp Immunol (1979) 2.04
The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man. J Immunol (1988) 2.00
IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med (1996) 1.93
Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1 beta and tumour necrosis factor-alpha. Immunology (1992) 1.93
IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology (1990) 1.85
Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products. Clin Exp Immunol (1982) 1.84
Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis (1991) 1.84
Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med (1995) 1.83
Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. Eur Respir J (2000) 1.81
T lymphocyte activation in acute severe asthma. Lancet (1988) 1.81
Identification and partial characterization of an exercise-induced neutrophil chemotactic factor in bronchial asthma. J Clin Invest (1982) 1.77
Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax (2003) 1.75
Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) (1981) 1.75
The identification of fibrinopeptide B as a chemotactic agent derived from human fibrinogen. Br J Haematol (1974) 1.70
Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol (1997) 1.69
Eosinophils 1992. Immunol Today (1992) 1.69
Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis (1992) 1.68
Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is alpha 4 beta 1 (very late antigen-4) dependent. J Immunol (1991) 1.67
The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today (1999) 1.67
Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol (1993) 1.67
Expression of chemokine receptors by lung T cells from normal and asthmatic subjects. J Immunol (2001) 1.67
Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest (1993) 1.66
Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med (1996) 1.64
Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med (1991) 1.64
Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol (1989) 1.63
Membrane receptors for IgG and complement (C4, C3b and C3d) on human eosinophils and neutrophils and their relation to eosinophilia. J Immunol (1977) 1.63
New insights into the role of the mast cell in asthma. Clin Exp Allergy (2003) 1.61
Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol (1997) 1.59
Preferential messenger RNA expression of Th1-type cells (IFN-gamma+, IL-2+) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin. J Immunol (1992) 1.59
Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood (1992) 1.59
Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol (1998) 1.57
Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4. Br J Pharmacol (1983) 1.56
The accumulation of 111In-eosinophils induced by inflammatory mediators, in vivo. Immunology (1991) 1.55
Killing of schistosomula of Schistosoma mansoni coated with antibody and/or complement by human leukocytes in vitro: requirement for complement in preferential killing by eosinophils. J Immunol (1979) 1.53
Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy (1999) 1.53
The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy (2005) 1.52
Interaction between isoprenaline and aminophylline in asthma. Thorax (1977) 1.52
Expression of CCR8 is increased in asthma. Clin Exp Allergy (2010) 1.51
Neutrophil chemotactic activity in antigen-induced late asthmatic reactions. N Engl J Med (1982) 1.51
Activated human eosinophils generate SRS-A leukotrienes following IgG-dependent stimulation. Nature (1985) 1.51
Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions. Clin Exp Allergy (2009) 1.51
Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med (1996) 1.50
Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med (1999) 1.48
Mediators of immediate-type hypersensitivity in sputum from patients with chronic bronchitis and asthma. Lancet (1977) 1.45
The ECF-A tetrapeptides and histamine selectively enhance human eosinophil complement receptors. Nature (1977) 1.43
CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am Rev Respir Dis (1993) 1.43
Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol (1995) 1.42
Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol (1995) 1.42
T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis (1992) 1.41
Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax (1993) 1.41
Eosinophil cytokines. Chem Immunol (2000) 1.41
Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med (1997) 1.39